This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
  • Ophthalmology
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Oncology
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
  • Cardiology
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
  • Women's Health
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
  • Ophthalmology Resources
  • Oncology Resources
  • Cardiology Resources
  • Women's Health Resources
  • Ophthalmology Events & On Demand Webinars
  • Oncology Events & On Demand Webinars
  • Cardiology Events & On Demand Webinars
  • Women's Health Events & On Demand Webinars
  • Ophthalmology Learning Zone
  • Oncology Learning Zone
  • Cardiology Learning Zone
  • Women's Health Learning Zone
  • Ophthalmology Podcasts
  • Oncology Podcasts
  • Cardiology Podcasts
  • Women's Health Podcasts
closesearch
Recent Searches
      EYLEA® (aflibercept) 8 mg
      Mechanism of Action
      Dosing
      Real World Experience
    • More...
    Eylea 8mg Logo
    EYLEA® (aflibercept) 8 mg
    Mechanism of Action
    Dosing
    Real World Experience
    • nAMD
    • DMO
    • RVO
    • HCP Resources
    • Pre-filled Syringe
    • Patient Support
    • Retinal Pioneers
    • Masterclass Programme
    • Risk Minimisation Materials
    • Ophthalmology Homepage
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    Close-up-eye

    Latest Highlights

    EYLEA 8 mg logo
    EYLEA® (aflibercept) 8 mg
    Discover data and resources about EYLEA 8 mg
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3129, March 2026
    RWE page content card
    Real World Experience
    Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3082, March 2026
    Retinal Pioneers page content card
    Retinal Pioneers Programme
    A source of on-demand, educational resources developed in collaboration with national and international thought leaders
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3102, March 2026
    Contact us - Ophthalmology
    Contact Bayer Ophthalmology
    Reach out directly to Bayer Ophthalmology with your enquiries.
    PP-EYL-GB-2995, September 2025

    Products

    EYLEA® (aflibercept) 8 mg
    Discover data and resources about EYLEA 8 mg
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3129, March 2026
    EYLEA® (aflibercept) 2 mg
    Discover data and resources about EYLEA 2 mg
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-2793, March 2025

    HCP Resources

    View more
    Real World Experience
    Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3082, March 2026
    Ophthalmology Resources
    Access useful, downloadable ophthalmology resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3081, March 2026
    Ophthalmology Patient Support Materials
    Access our range of downloadable patient support booklets and other resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3117, March 2026
    EYLEA® (aflibercept) Risk Minimisation Materials
    Visit to access Risk Minimisation Materials for EYLEA® (aflibercept)
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-2647, December 2024

    Patient Support Materials

    Ophthalmology Patient Support Materials
    Access our range of downloadable patient support booklets and other resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3117, March 2026

    Learning Zone

    View more
    Bayer Ophthalmology Masterclass Programme
    Interactive meetings and online resources to refresh your knowledge
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-2858, March 2026

    Retinal Pioneers Programme

    Retinal Pioneers Programme
    A source of on-demand, educational resources developed in collaboration with national and international thought leaders
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3102, March 2026

    Podcasts

    View more
    The Macular Minute: Podcast Series
    Your source for quick expert insights in medical retina
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3090, March 2026